The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer.
 
Judong Li
No Relationships to Disclose
 
Wei Wei
No Relationships to Disclose
 
Ziyi Wang
No Relationships to Disclose
 
Xin Zhang
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Hao Yu
No Relationships to Disclose
 
Hongying Yang
No Relationships to Disclose
 
Xiumin Li
No Relationships to Disclose
 
Li Li
No Relationships to Disclose
 
Xiujie Sheng
No Relationships to Disclose
 
Jun Gao
No Relationships to Disclose
 
Chang Liu
No Relationships to Disclose
 
Yuanhuan Xiong
No Relationships to Disclose
 
Jinmei Yu
No Relationships to Disclose
 
Yi Huang
No Relationships to Disclose
 
Li Sun
No Relationships to Disclose
 
Zhu Qiao
No Relationships to Disclose
 
Xiangyang Zhu
Employment - Huaota Biopharm
Leadership - Huaota Biopharm
Honoraria - Huaota Biopharm
Research Funding - Huaota Biopharm
 
Xiuqiang Ma
Employment - Huaota Biopharm
Honoraria - Huaota Biopharm
 
Lee Li
Employment - Huaota Biopharm
Honoraria - Huaota Biopharm